ETOX ProjectETOX ProjectETOX ProjectETOX ProjectETOX ProjectETOX Project
  Home > Consortium > Advisory board
ETOX Project Print page ETOX Project Send page


Consortium - List of partners


ETOX Project line

Advisory board


Advisory board


Robert J Kavlock, Ph.D.


Dr. Kavlock is the Deputy Assistant Administrator for science in EPA's Office of Research and Development (ORD). He has over 33 years of scientific experience and was previously the Director of the National Center for Computational Toxicology (NCCT) within ORD, a post he occupied since its founding in 2005. The ToxCast program within the NCCT is on the leading edge of the state of the science in computational toxicology. Dr. Kavlock began his career at EPA in 1977 conducting research on the effects of pesticides on prenatal development and progressed to spending 15 years as the Director of the Reproductive Toxicology Division in ORD. He has spent much of his career working on improving the basis for understanding non-cancer health effects, with the most recent efforts focused on computational toxicology. Computational toxicology promises to transform the conduct of toxicological studies through the blending of advances in modern molecular biology with computational sciences. Dr. Kavlock has published more than 200 scientific papers, 16 book chapters, edited three books, including co-editor of the Global Assessment of the State-of-the-Science of Endocrine Disruptors (WHO, 2002) and serves on a number of international scientific advisory committees. He is the co-recipient of the U.S.Human Society North American Alternative Award (2008), ORDís Statesmen of the Year Award (2007) and is past president of the Teratology Society. Dr. Kavlock also serves as a member of the editorial boards of Environmental Health Perspectives, the Journal of Toxicology and Environmental Health, and Birth Defects Research Part B: Developmental and Reproductive Toxicity. Dr. Kavlock was also instrumental to establish the contact between ToxCast/Tox21 and eTOX for data sharing.



Peter Kasper, Ph.D.


Dr. Peter Kasper is a Director and Professor at the Federal Institute for Drugs and Medical Devices (BfArM) in Bonn, Germany, where he currently serves as toxicologist in preclinical safety sciences. Dr. Kasper received his PhD in biology/genetics from the Free University of Berlin. In 1986, he joined the German Federal Health Agency in Berlin as a research fellow. Since 1989 he worked as a non-clinical assessor in the regulatory review process at the BfArM and was Head of the Genetic Toxicology Unit at BfArM from 1999 to 2005. He is/has been member of several CHMP Working Parties (Safety, Pharmacogenomics, 3Rs) at the European Medicines Agency and EU topic leader in the ICH process for the ICH S2, Q3C and M7 guidelines. Dr. Kasper was vice president of the German Environmental Mutagen Society, national Councillor of the European Environmental Mutagen Society and has served on numerous international expert committees and organizations. Dr. Kasper has authored and co-authored more than 80 peer reviewed publications in the area of genetic toxicology and regulatory safety sciences.



Markku Pasanen, Prof.


Dr. Pasanen is a member of the EMA's Scientific Advice Working Party and has worked as a Professor in Medical Toxicology at the University of Kuopio in Finland (1990-1995), then as senior medical officer at the Finnish Medicines Agency (NAM), Helsinki Finland. His present position (from 2006) is professor of medicinal toxicology at the University of Eastern Finland, Faculty of Health Sciences, Kuopio, (Finland). He is an external non-clinical expert of the European Medicines Agency (EMA) being nominated as a member in CHMP Scientific Advice (SAWP), Safety (SWP), and Pharmacogenetics (PgWP) working parties.



Darrell R. Abernethy, M.D., Ph.D.


Dr. Darrell R. Abernethy, M.D., Ph.D. is responsible for leading the development of a pharmacological mechanism based safety program in the Office of Clinical Pharmacology to work in synergy with efforts in the Office of Surveillance and Epidemiology and other Offices and Centers at FDA. Dr. Abernethy brings more than 25 years of experience in medicine and pharmacology, including positions in academia, practice and research. Prior to joining FDA he served as Chief Science Officer at USP.